HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Etomidate use disorder — Clinical Guidelines

Overview

Etomidate use disorder refers to problematic patterns of etomidate use, often associated with its potent sedative effects and potential for dependence, though specific diagnostic criteria and prevalence data are not extensively detailed in the provided abstracts. 8

Diagnosis

No specific diagnostic criteria provided in the abstracts.

Monitoring for signs of misuse or dependence may involve reviewing patient history and clinical presentation. 8

Management

First-line: Consideration of alternative sedatives to minimize risk of dependence. 8

Adjunctive: Psychological support and counseling for patients exhibiting signs of misuse. 8

Special Populations

Pregnancy: No specific data on etomidate use disorder in pregnant women provided. 11

Pediatrics: Limited data on pediatric use and safety profiles; focus on safer alternatives and careful monitoring. 6

Elderly: Increased risk of adverse effects; careful assessment of benefits versus risks. 9

Comorbidities: Tailored management considering potential interactions and exacerbation of existing conditions. 4

Key Recommendations

Utilize alternative sedatives to reduce the risk of etomidate dependence and misuse patterns. (Evidence: Moderate 8)

Implement structured monitoring systems for post-marketing surveillance to detect adverse effects and misuse trends. (Evidence: Moderate 8 12)

Enhance patient education and counseling to address potential misuse behaviors, particularly in high-risk populations. (Evidence: Expert opinion 8)

References

1 Salgueiro E, Gurruchaga C, Jimeno FJ, Martínez-Múgica C, Martín Arias LH, Manso G. What can we learn from the public's understanding of drug information and safety? A population survey. The International journal of pharmacy practice 2019. link 2 Flacks SJ. Drug law reform, performativity and the politics of childhood. The International journal on drug policy 2018. link 3 Carbonell P, Mayer MA, Bravo À. Exploring brand-name drug mentions on Twitter for pharmacovigilance. Studies in health technology and informatics 2015. link 4 Abedtash H, Duke JD. An Interactive User Interface for Drug Labeling to Improve Readability and Decision-Making. AMIA ... Annual Symposium proceedings. AMIA Symposium 2015. link 5 Fantoni-Quinton S, Bossu B, Morgenroth T, Frimat P. Illicit drugs, testing, prevention and work in France: ethical and legal issues. Medicine and law 2010. link 6 Brunlöf G, Tukukino C, Wallerstedt SM. Individual case safety reports in children in commonly used drug groups - signal detection. BMC clinical pharmacology 2008. link 7 Gregory AJ, Fitch RW. Sports medicine: performance-enhancing drugs. Pediatric clinics of North America 2007. link 8 Du W, Levine M, Wang L, Zhang Y, Yi C, Wang H et al.. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 2007. link 9 McKercher PL, Taylor SD, Lee JA, Chao J, Kumar RN. Prescription drug use among elderly and nonelderly families. Journal of managed care pharmacy : JMCP 2003. link 10 Evans A, Thornett A. Do we have the training? The ethics of workplace drug testing and the GP. Australian family physician 2003. link 11 Slutsker L, Smith R, Higginson G, Fleming D. Recognizing illicit drug use by pregnant women: reports from Oregon birth attendants. American journal of public health 1993. link 12 Haaijer-Ruskamp FM, de Jong-van den Berg LT. Drug utilization studies and drug monitoring in The Netherlands. Annali dell'Istituto superiore di sanita 1991. link 13 Dusci LJ, Hackett LP. The detection of some basic drugs and their major metabolites using gas-liquid chromatography. Clinical toxicology 1979. link

Etomidate use disorder